Email this article Experience with 13-valent conjugated pneumococcal vaccine in HIV-infected patients
- Authors: Zhestkov A.V.1, Zolotov M.O.1, Lyamin A.V.1, Borisova O.V.1, Chernova O.E.2, Limareva L.V.1, Ismatullin D.D.1
-
Affiliations:
- Samara State Medical University
- Samara Regional Clinical Center for AIDS Prevention and Control
- Issue: Vol 92, No 11 (2020)
- Pages: 38-44
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/56928
- DOI: https://doi.org/10.26442/00403660.2020.11.000861
- ID: 56928
Cite item
Full Text
Abstract
Aim. Evaluate the effect of PCV13 vaccination on the composition of the microflora of the upper respiratory tract and the immune system in HIV-infected patients.
Materials and methods. 100 patients with HIV-infection were included in the study. The patients underwent immunological examination and the collection of biomaterial from the posterior pharyngeal wall for microbiological examination. After obtaining the results of the examinations, PCV13 was intramuscularly administered. 7 days after the introduction of the vaccine, an assessment of adverse events was carried out, after 3 months, microbiological and immunological examinations were repeated.
Results. Immediately after the administration of PCV13, 5% of patients felt pain during the administration. Local reactions were reported in 6 patients. One participant showed a rise in temperature to 38.3°C over 2 days. Before vaccination, 16 strains of S. pneumoniae were seeded in patients. 3 months after the administration of PCV13, pneumococcus was isolated in 8 patients. 3 months after immunization, the median level of populations and subpopulations of lymphocytes became higher than the pre-vaccination.
Discussion. Our results show high risk of pneumococcal infections in HIV-positive patients. A tendency towards a decrease in the level of S. pneumoniae carriage was revealed 3 months after the administration of PCV13. The high level of enterobacteria carriage in HIV-positive patients is noteworthy. There is a pronounced positive effect from the use of PCV13 in HIV-positive patients on cellular factors of the immune system.
Conclusion. The use of PCV13 is a safe and effective method for the prevention of S. pneumoniae infections.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A. V. Zhestkov
Samara State Medical University
Author for correspondence.
Email: m.o.zolotov@gmail.com
ORCID iD: 0000-0002-3960-830X
д.м.н, проф., зав. каф. общей и клинической микробиологии, иммунологии и аллергологии
Russian Federation, SamaraM. O. Zolotov
Samara State Medical University
Email: m.o.zolotov@gmail.com
ORCID iD: 0000-0002-4806-050X
очный аспирант каф. общей и клинической микробиологии, иммунологии и аллергологии
Russian Federation, SamaraA. V. Lyamin
Samara State Medical University
Email: m.o.zolotov@gmail.com
ORCID iD: 0000-0002-5905-1895
к.м.н., доц. каф. общей и клинической микробиологии, иммунологии и аллергологии
Russian Federation, SamaraO. V. Borisova
Samara State Medical University
Email: m.o.zolotov@gmail.com
ORCID iD: 0000-0003-1430-6708
д.м.н., проф. каф. детских инфекций
Russian Federation, SamaraO. E. Chernova
Samara Regional Clinical Center for AIDS Prevention and Control
Email: m.o.zolotov@gmail.com
ORCID iD: 0000-0003-4600-0738
к.м.н., глав. врач
Russian Federation, SamaraL. V. Limareva
Samara State Medical University
Email: m.o.zolotov@gmail.com
ORCID iD: 0000-0003-4529-5896
д.б.н, проф. каф. общей и клинической микробиологии, иммунологии и аллергологии, дир.
Russian Federation, SamaraD. D. Ismatullin
Samara State Medical University
Email: m.o.zolotov@gmail.com
ORCID iD: 0000-0002-4283-907X
ассистент каф. общей и клинической микробиологии, иммунологии и аллергологии
Russian Federation, SamaraReferences
- Краснова Е.И., Хохлова Н.И., Проворова В.В. и др. Анализ эпидемиологических данных по ВИЧ-инфекции на современном этапе. Journal of Siberian Medical Sciences. 2018;1:84-95 [Krasnova EI, Khokhlova NI, Provorova VV, et al. Analysis of present-day HIV-infection epidemiological data. Journal of Siberian Medical Sciences. 2018;1:84-95 (In Russ.)].
- Зверев С.Я., Иванова Э.С., Лузин П.М. Вопросы эпидемиологии, диагностики, клиники и профилактики ВИЧ-инфекции в Прикамье. Метод. рекомендации. Пермь: ГКУЗ КПЦ СПИД и ИЗ, 2014 [Zverev SYa, Ivanov ES, Luzin PM, et al. Issues of epidemiology, diagnosis, clinic and HIV prevention in Prikamye. Method. recommendations. Perm: GKUZ KPC SPID i IZ, 2014 (In Russ.)].
- Ватутин Н.Т., Колесников В.С., Тараторина А.А. и др. Особенности течения пневмонии у ВИЧ-инфицированных пациентов. Архивъ внутренней медицины. 2016;6(1):71-6 [Vatutin NT, Kolesnikov VS, Taratorina AA, et al. Features of pneumonia in HIV-infected patients. Arhiv vnutrennej mediciny. 2016;6(1):71-6 (In Russ.)]. doi: 10.20514/2226-6704-2016-6-1-71-76
- Мишин В.Ю., Протасов А.Д., Жестков А.В. Заболевания легких у пациентов с ВИЧ-инфекцией. В кн.: Респираторная медицина: руководство. В 3 т. Под ред А.Г. Чучалина. М., 2017; с. 251-63 [Mishin VYu, Protasov AD, Zhestkov AV. Lung diseases in patients with HIV infection. In: Respiratory medicine. Guide in 3 vol. Ed. by A.G. Chuchalin. Moscow, 2017; p. 251-63 (In Russ.)].
- Пузырева Л.В., Сафонов А.Д., Мордык А.В. Заболевания органов дыхания при ВИЧ-инфекции (обзор). Журнал инфектологии. 2016;8(2):17-25 [Puzyryova LV, Safonov AD, Mordyk AV. Respiratory diseases with HIV infection (review). Zhurnal infektologii. 2016;8(2):17-25 (In Russ.)].
- Madeddu G, Fiori ML, Mura MS. Bacterial community-acquired pneumonia in HIV-infected patients. Curr Opin Pulm Med. 2010;16(3):201-7. doi: 10.1097/MCP.0b013e3283375825
- Feldman C, Anderson R. Bacterial community-acquired pneumonia. In: Pulmonary complications of HIV. Ed. by Feldman C, Polverino E, Ramirez JA. Norwich: Page Bros Ltd. 2014; p. 98-111.
- Сабитова Р.Я. Изменения иммунограммы и особенности клинических проявлений при тяжелой внебольничной пневмонии у ВИЧ-инфицированных. Практическая медицина. 2012;6(61):43-6 [Sabitova RYa. Immunogram changes and clinical manifestations in severe community-acquired pneumonia in HIV-infected patients. Prakticheskaya medicina. 2012;6(61):43-6 (In Russ.)].
- Галкина-Лазарева Е.В. Эффективность профилактики пневмококковых инфекций. Вопр. совр. педиатрии. 2012;11(3):12-7 [Galkina-Lazareva ЕV. The effectiveness of the prevention of pneumococcal infections. Vopr. sovr. pediatrii. 2012;11(3):12-7 (In Russ.)].
- Елистратова Т.А, Протасова Н.И., Сергеева И.В. Роль микрофлоры верхних дыхательных путей в развитии оппортунистических инфекций у пациентов с ВИЧ. Дневник казанской мед. школы. 2015:2(8):60 [Еlistratova TA, Protasova NI, Sergeeva IV. The role of microflora in the upper respiratory tract in the development of opportunistic infections in HIV patients. Dnevnik kazanskoj med. shkoly. 2015;2(8):60 (In Russ.)].
- Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother. 2012;8(2):161-73. doi: 10.4161/hv.18432
- Руководство по медицинской микробиологии. Частная медицинская микробиология и этиологическая диагностика инфекций. Книга II. Под ред. А.С. Лабинской, Н.Н. Костюковой, С.М. Ивановой. М.: Бином, 2012 [Guide to medical microbiology. Private medical microbiology and etiological diagnosis of infections. Book II. Ed. by A.S. Labinskaya, N.N. Kostyukova, S.M. Ivanova. Moscow: Binom, 2012 (In Russ.)].
- Баранов А.А., Намазова-Баранова Л.С., Брико Н.И. и др. Вакцинопрофилактика пневмококковой инфекции у детей. Педиатрическая фармакология. 2018;15(3):200-11 [Baranov AA, Namazova-Baranova LS, Briko NI, et al. Vaccination of pneumococcal infection in children. Pediatricheskaya farmakologiya. 2018;15(3):200-11 (In Russ.)]. doi: 10.15690/pf.v15i3.1899
- Намазова-Баранова Л.С., Федосеенко М.В., Вишнева Е.А. и др. Теоретические основы и реальные результаты: обзор материалов по вакцинопрофилактике пневмококковой инфекции в мире. Педиатрическая фармакология. 2018;15(1):58-74 [Namazova-Baranova LS, Fedoseenko MV, Vishnyova EA, et al. Theoretical foundations and real results: a review of materials on vaccine prophylaxis of pneumococcal infection in the world. Pediatricheskaya farmakologiya. 2018;15(1):58-74 (In Russ.)]. doi: 10.15690/pf.v15i1.1844
- Харит С.М., Перова Л.М. Современные подходы к профилактике пневмококковой инфекции. Мед. совет. 2015;16:64-7 [Harit SM, Perova LM. Modern approaches to the prevention of pneumococcal infection. Medicinskij sovet. 2015;16:64-7 (In Russ.)]. doi: 10.21518/2079-701X-2015-16-64-67
- Вакцины и вакцинация. Национальное руководство. Краткое издание. Под ред. В.В. Зверева, Р.М. Хаитова. М.: ГЭОТАР-Медиа, 2014 [Vaccines and vaccination. National leadership. Brief Edition ed. by VV Zverev, RM Haitov. Moscow: GEOTAR-Media, 2014 (In Russ.)].
- Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213-20. doi: 10.1038/nri2494
- Glesby MJ, Watson W, Brinson C, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine. J Infect Dis. 2015;212(1):18-27. doi: 10.1093/infdis/jiu631
- Bhorat AE, Madhi SA, Laudat F, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015;29(11):1345-54. doi: 10.1097/QAD.0000000000000689
- Сафиуллин А.И., Аскарова Л.И., Мирахмедова Н.Н., Папина Е.С. Концентрация иммуноглобулинов основных классов (A, M, G) в крови и слюне у ВИЧ-инфицированных с оральными поражениями. Журн. теоретич. и клин. медицины. 2015;2:130-2 [Safiullin AI, Askarova LI, Mirahmedova NN, Papina ES. The concentration of immunoglobulins of the main classes (A, M, G) in the blood and saliva in HIV-infected patients with oral lesions. Zhurn. teoretich. i kiln. mediciny. 2015;2:130-2 (In Russ.)].
Supplementary files
